Press Release Archive | EOM Pharmaceuticals, Inc.

Press Release Archive

November 7, 2023

EOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613

September 13, 2023

EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil

November 10, 2022

EOM PHARMACEUTICAL HOLDINGS, INC. ANNOUNCES NAME CHANGE FROM IMMUNOCELLULAR THERAPEUTICS, LTD.

December 2, 2021

EOM PHARMACEUTICALS, INC. AND IMMUNOCELLULAR THERAPEUTICS, LTD. ANNOUNCE ENTRY INTO AND CLOSE OF DEFINITIVE MERGER AGREEMENT

August 24, 2021

EOM PHARMACEUTICALS ANNOUNCES FIRST PATIENTS DOSED IN R1: RESCUE PHASE 1/2A OPEN-LABEL TRIAL EVALUATING EOM613 IN HOSPITALIZED COVID-19 PATIENTS WITH SEVERE SYMPTOMS IN BRAZIL

July 22, 2021

EOM PHARMACEUTICALS APPOINTS DRUG DEVELOPMENT VETERAN FRANK L. DOUGLAS, Ph.D., M.D., SCIENTIFIC ADVISOR

December 24, 2020

EOM PHARMACEUTICALS ANNOUNCES ITS PRE-IND MEETING REQUEST WITH U.S. FDA TO EVALUATE PLANS FOR A PHASE 2 CLINICAL TRIAL OF ITS INVESTIGATIONAL DUAL-ACTING, BROAD-SPECTRUM IMMUNOMODULATOR IN COVID-19 PATIENTS

December 17, 2020

EOM PHARMACEUTICALS APPOINTS BUSINESS VETERAN WAYNE I. DANSON AS CHIEF FINANCIAL OFFICER AND TREASURER